No dedicated clinical trials have compared denosumab and bisphosphonates for fracture prevention in patients on dialysis.

In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...

(HealthDay News) — For dialysis-dependent patients treated for osteoporosis, denosumab is associated with a greater preventive effect on fractures but an increased risk for major adverse ...

FDA committee recommends Amgen's denosumab, for the treatment, but not prevention, of bone loss, while Lilly decides not to submit arzoxifene for regulatory review after 5-year trial. Later this ...

Number 4: Celltrion’s denosumab biosimilar demonstrated equivalent efficacy, safety, and immunogenicity compared with the ...

Sandoz has claimed the first FDA approvals for biosimilars of Amgen’s blockbuster bone disease therapy denosumab, but has not said when it plans to launch them onto the US market. Amgen sells ...

Pharmac is widening access to a medicine called denosumab for people with osteoporosis. A higher dose of the medicine will also be funded for people with cancer who have high levels of calcium in ...

In this target trial emulation study, denosumab was associated with an increased risk of major adverse cardiovascular events ...

The phase 1/3 ROSALIA study showed that the copycat denosumab matched Amgen's brand on multiple pharmacokinetics, pharmacodynamics, efficacy, safety, and immunogenicity measures in postmenopausal ...

Pharmac is widening access to a medicine called denosumab for people with osteoporosis. A higher dose of the medicine will also be funded for people with cancer who have high levels of calcium in ...

New Zealand’s medicine-funding agency Pharmac is widening access to a medicine called denosumab for people with osteoporosis.